Alexion 1Q Revenues: $600.3 million (+6%) 1Q Earnings: $91.3 million (-43%) Comments: Sales of Soliris were $600.3 million, up 6%. The company entered three agreements in 1Q for the clinical development and commercialization of drug products and recorded R&D expense for upfront payments of $112.0 million. Restructuring expenses in the quarter related to the relocation of its European headquarters from Lausanne to Zurich, were $7.1 million....